111 related articles for article (PubMed ID: 32900626)
1. The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?
Ieiri K; Shiota M; Kashiwagi E; Takeuchi A; Takahashi R; Inokuchi J; Iwai H; Shiga KI; Yokomizo A; Yoshitake T; Shioyama Y; Ishigami K; Terashima H; Eto M
Urol Oncol; 2020 Dec; 38(12):931.e1-931.e7. PubMed ID: 32900626
[TBL] [Abstract][Full Text] [Related]
2. Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
Blas L; Shiota M; Yamada S; Ieiri K; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Res; 2021 Aug; 41(8):3885-3889. PubMed ID: 34281850
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer.
Blas L; Ieiri K; Shiota M; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Res; 2021 Nov; 41(11):5593-5598. PubMed ID: 34732430
[TBL] [Abstract][Full Text] [Related]
4. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Outcomes in Patients With Clinically Lymph Node Positive Prostate Cancer After Definitive Radiotherapy.
Kim TH; Kim DY; Kim JS
In Vivo; 2023; 37(5):2365-2370. PubMed ID: 37652494
[TBL] [Abstract][Full Text] [Related]
6. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
[TBL] [Abstract][Full Text] [Related]
7. Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.
Grivas N; Wit E; Pos F; de Jong J; Vegt E; Bex A; Hendricksen K; Horenblas S; KleinJan G; van Rhijn B; van der Poel H
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):347-354. PubMed ID: 28068243
[TBL] [Abstract][Full Text] [Related]
8. Risk of prostate carcinoma death in patients with lymph node metastasis.
Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
[TBL] [Abstract][Full Text] [Related]
9. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
[TBL] [Abstract][Full Text] [Related]
11. Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection.
Abdollah F; Dalela D; Sood A; Keeley J; Alanee S; Briganti A; Montorsi F; Peabody JO; Menon M
Eur Urol; 2018 Sep; 74(3):253-256. PubMed ID: 29720348
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
13. Incidence of lymph node metastasis and its impact on long-term prognosis in clinically localized prostate cancer.
Arai Y; Kanamaru H; Yoshimura K; Okubo K; Kamoto T; Yoshida O
Int J Urol; 1998 Sep; 5(5):459-65. PubMed ID: 9781435
[TBL] [Abstract][Full Text] [Related]
14. Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis.
Umezawa R; Inaba K; Nakamura S; Wakita A; Okamoto H; Shima S; Tsuchida K; Kashihara T; Kobayashi K; Harada K; Takahashi K; Murakami N; Ito Y; Igaki H; Jingu K; Itami J
Anticancer Res; 2018 Apr; 38(4):2303-2309. PubMed ID: 29599353
[TBL] [Abstract][Full Text] [Related]
15. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
16. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
[TBL] [Abstract][Full Text] [Related]
18. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer.
Tsuchida K; Inaba K; Kashihara T; Murakami N; Okuma K; Takahashi K; Igaki H; Nakayama Y; Maejima A; Shinoda Y; Matsui Y; Komiyama M; Fujimoto H; Ito Y; Sumi M; Nakano T; Itami J
Cancer Med; 2020 Sep; 9(18):6629-6637. PubMed ID: 32750234
[TBL] [Abstract][Full Text] [Related]
20. Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.
Gugliemetti G; Sukhu R; Conca Baenas MA; Meeks J; Sjoberg DD; Eastham JA; Scardino PT; Touijer K
Actas Urol Esp; 2016 Sep; 40(7):434-9. PubMed ID: 27184342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
